Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GERN Geron

Pre-Market Trading 11-26 08:31:06 EST

4.10

+0.03

+0.74%

盘前4.13

+0.03+0.73%

08:20 EST

High4.20	Low4.08	Vol7.70M
Open4.10	D1 Closing4.07	Amplitude2.95%
Mkt Cap2.48B	Tradable Cap2.16B	Total Shares604.50M
T/O31.71M	T/O Rate1.46%	Tradable Shares527.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GERN","market":"US","secType":"STK","nameCN":"Geron","latestPrice":4.1,"timestamp":1732568400000,"preClose":4.07,"halted":0,"volume":7696994,"hourTrading":{"tag":"盘前","latestPrice":4.13,"preClose":4.1,"latestTime":"08:20 EST","volume":413,"amount":1645.3851855,"timestamp":1732627202786},"delay":0,"floatShares":527391047,"shares":604501016,"eps":-0.319983,"marketStatus":"Pre-Market Trading","change":0.03,"latestTime":"11-26 08:31:06 EST","open":4.1,"high":4.2,"low":4.08,"amount":31712326.482245598,"amplitude":0.029484,"askPrice":4.19,"askSize":100,"bidPrice":4.08,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-0.319983,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732631400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":838699200000,"exchange":"NASDAQ","adjPreClose":4.1,"preHourTrading":{"tag":"盘前","latestPrice":4.13,"preClose":4.1,"latestTime":"08:20 EST","volume":413,"amount":1645.3851855,"timestamp":1732627202786},"postHourTrading":{"tag":"盘后","latestPrice":4.1,"preClose":4.1,"latestTime":"19:43 EST","volume":422996,"amount":1734045.8269,"timestamp":1732581790409},"volumeRatio":0.8329380843357844,"impliedVol":0.3674,"impliedVolPercentile":0.1071},"requestUrl":"/m/hq/s/GERN/tweets","defaultTab":"tweets","newsList":[{"id":"2485308425","title":"Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485308425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485308425?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:30","pubTimestamp":1732224601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA2GN2GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","BK4112","BK4588","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","BK4139","GERN","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2485426805","title":"Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485426805","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485426805?lang=en_us&edition=fundamental","pubTime":"2024-11-22 05:30","pubTimestamp":1732224600,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., November 21, 2024----Geron Corporation , a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 1,017,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.Kristen KelleherAssociate Director, Investor Relations and Corporate Communications","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MxCLjLvtHsCmi.MvH9ykcw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42aa4b2fb866fdad8f4be7a9ceb14758","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MxCLjLvtHsCmi.MvH9ykcw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/42aa4b2fb866fdad8f4be7a9ceb14758"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-reports-inducement-grants-under-213000916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QID","TQQQ","IE00B3QW5Z07.USD","MNQmain","BK4585","LU2095319765.USD","NQmain","PSQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","NDAQ",".IXIC","IE00BKPKM429.USD","GERN","LU2210150020.SGD","QLD","LU2210149790.SGD","BK4588","SQQQ","BK4139"],"gpt_icon":1},{"id":"2485008442","title":"Geron: A Strong Launch And Financial Deals Make It Attractive","url":"https://stock-news.laohu8.com/highlight/detail?id=2485008442","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485008442?lang=en_us&edition=fundamental","pubTime":"2024-11-22 04:05","pubTimestamp":1732219501,"startTime":"0","endTime":"0","summary":"Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat.Analysts are bullish, with H.C. Wainwr","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4739408-geron-a-strong-launch-and-financial-deals-make-it-attractive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["GERN","BK4139"],"gpt_icon":1},{"id":"2485044564","title":"High Growth Tech Stocks to Watch in November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485044564","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485044564?lang=en_us&edition=fundamental","pubTime":"2024-11-22 02:02","pubTimestamp":1732212171,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped by 1.0%, yet in the longer term, it has risen by 30% over the past year with earnings forecasted to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves evaluating companies that demonstrate robust innovation and adaptability to capitalize on emerging opportunities.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.Operations: Crane NXT generates revenue primarily from two segments: Crane Payment Innovations, contributing $873.40 million, and Security and Authentication Technologies with $571.20 million.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nzKrm42FSn6V71xz6p35kw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a49a47a9f32b0da2b60e02ee1083081b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nzKrm42FSn6V71xz6p35kw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a49a47a9f32b0da2b60e02ee1083081b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-180251716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GERN","LGF.A","BK4108","CXT","BK4161","BK4157"],"gpt_icon":0},{"id":"2482676664","title":"Geron Corporation Announces Appointment of Joseph Eid, M.d. as Executive Vice President, Research and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2482676664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482676664?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:30","pubTimestamp":1731360600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA2STQFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GERN"],"gpt_icon":0},{"id":"2482984769","title":"Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2482984769","media":"Business Wire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482984769?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:30","pubTimestamp":1731360600,"startTime":"0","endTime":"0","summary":"\"Joe has a deeply impressive track record of more than two decades of global leadership and expertise driving drug development, regulatory, and commercial success for small and large biopharmaceutical companies, including broad experience across hematology and oncology,\" said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. \"We are thrilled to welcome him to Geron to oversee an integrated, cross-functional R&D organization that is structured to optimize performance and collaboration as a commercial company and to support this exciting era of growth for our company. With the recent addition of Jim Ziegler to lead our commercial organization, Dr. Faye Feller continuing as Chief Medical Officer, and now Joe’s appointment to lead our R&D organization, we feel even more confident in our continued efforts to deliver RYTELO to eligible patients in need, drive innovation, expand Geron’s global footprint in hematologic malignancies and invest in our ability to change patien","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/91izkgy4F19PyniTUZ3a1A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b09b4d678b519a8f70c448026f8c7f65","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/91izkgy4F19PyniTUZ3a1A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b09b4d678b519a8f70c448026f8c7f65"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corporation-announces-appointment-joseph-213000601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0265550946.USD","LU0965509283.SGD","LU0265550359.USD","LU1061106388.HKD","LU1941712264.USD","IE00B4R5TH58.HKD","LU0320765489.SGD","BK4588","LU0211331839.USD","LU0058720904.USD","IE00BLSP4452.SGD","MRK","LU0122379950.USD","LU0238689110.USD","IE00BBT3K403.USD","LU1585245621.USD","IE00BJT1NW94.SGD","LU1066051498.USD","LU1066051811.HKD","IE0009355771.USD","IE000M9KFDE8.USD","LU0985320562.USD","BK4139","LU0861579265.USD","LU1116320901.HKD","LU1023059063.AUD","LU1934455194.USD","LU1037948541.HKD","IE0002141913.USD","LU1037948897.HKD","LU1093756325.SGD","LU1057294990.SGD","IE00BLSP4239.USD","LU0106261372.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","IE00B1BXHZ80.USD","BK4550","LU0203347892.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU1934455863.HKD","LU0208291251.USD","GERN","LU1291159041.SGD","IE00B2B36J28.USD","BK4533","LU0289739699.SGD","BK4585","LU0965509101.SGD"],"gpt_icon":0},{"id":"2482822287","title":"Geron to Participate in the Stifel 2024 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2482822287","media":"Business Wire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482822287?lang=en_us&edition=fundamental","pubTime":"2024-11-11 22:00","pubTimestamp":1731333600,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., November 11, 2024----Geron Corporation , a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to participate in a fireside chat at the Stifel 2024 Healthcare Conference, in New York City, on Monday, November 18th, 2024, at 1:50pm ET.A webcast of the fireside chat will be available through the Investors and Media section of Geron’s website under Events following the presentation. The webcast will be archived and available for replay for a period of 30 days.Kristen KelleherAssociate Director, Investor Relations and Corporate Communications","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jIaDxkFVxzbVZwzl55CBzw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/96c659ab65c6022f7a373c3c2e04cbbd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jIaDxkFVxzbVZwzl55CBzw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/96c659ab65c6022f7a373c3c2e04cbbd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-participate-stifel-2024-healthcare-140000917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SF","HCSG","GERN","BK4127","BK4139","BK4137"],"gpt_icon":0},{"id":"2482786364","title":"TD Cowen Reaffirms Their Buy Rating on Geron (GERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786364?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:47","pubTimestamp":1731329231,"startTime":"0","endTime":"0","summary":"In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Geron (GERN – Research Report), with a price target of $10.00. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-geron-gern?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-geron-gern?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","GERN"],"gpt_icon":0},{"id":"2482822406","title":"Geron: Strong Sales Momentum and Strategic Financial Decisions Support ‘Buy’ Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2482822406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482822406?lang=en_us&edition=fundamental","pubTime":"2024-11-11 14:29","pubTimestamp":1731306557,"startTime":"0","endTime":"0","summary":"Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on Geron (GERN – Research Report) and keeping the price target at $7.00. Fais...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/geron-strong-sales-momentum-and-strategic-financial-decisions-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/geron-strong-sales-momentum-and-strategic-financial-decisions-support-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GERN"],"gpt_icon":0},{"id":"2482243904","title":"Stifel Nicolaus Remains a Buy on Geron (GERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482243904","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482243904?lang=en_us&edition=fundamental","pubTime":"2024-11-11 10:06","pubTimestamp":1731290770,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Geron (GERN – Research Report) on November 8 and set a price target of $8.00. The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-geron-gern?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-geron-gern?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","GERN","SF","BK4139"],"gpt_icon":0},{"id":"2482841447","title":"Geron Third Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482841447","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482841447?lang=en_us&edition=fundamental","pubTime":"2024-11-09 20:15","pubTimestamp":1731154513,"startTime":"0","endTime":"0","summary":"NasdaqGS:GERN Earnings and Revenue Growth November 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 49%. Earnings per share  also surpassed analyst estimates by 53%.Looking ahead, revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are up 3.4% from a week ago.Be aware that  Geron is showing  1 warning sign in our investment analysis that you should know about...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-third-quarter-2024-earnings-121513264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GERN"],"gpt_icon":0},{"id":"2481103987","title":"Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481103987","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481103987?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:00","pubTimestamp":1731070841,"startTime":"0","endTime":"0","summary":"Rytelo Net Product Revenue: $28.2 million in the first full quarter of U.S. sales.Total Net Revenue: $28.3 million for Q3 2024.Cash and Marketable Securities: Approximately $542.4 million on a pro forma basis as of September 30, 2024.Total Operating Expenses: $56.5 million for Q3 2024.Research and Development Expenses: $20.2 million for Q3 2024.Selling, General, and Administrative Expenses: $35.9 million for Q3 2024.Cost of Goods Sold: Approximately $450,000 for Q3 2024.Debt Financing and Royalty Transactions: $250 million in gross proceeds from a synthetic royalty transaction and debt financing.Projected Operating Expenses for FY 2024: Expected to be in the range of $260 million to $270 million.GuruFocus has detected 5 Warning Signs with GERN.Geron Corp  achieved $28.2 million in Rytelo net product revenue in its first full quarter, exceeding expectations.Geron Corp  completed a synthetic royalty transaction and a debt financing transaction, generating $250 million in gross proceeds.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/00GoUv6CquqN1seUbxq.0A--~B/aD05OTt3PTE4MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/fbb0a38c8039bad2b1a165db7b8b267a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/00GoUv6CquqN1seUbxq.0A--~B/aD05OTt3PTE4MzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/fbb0a38c8039bad2b1a165db7b8b267a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-corp-gern-q3-2024-130041252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GERN"],"gpt_icon":0},{"id":"2481747321","title":"Geron Secures $250M Funding and Strong Q3 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2481747321","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481747321?lang=en_us&edition=fundamental","pubTime":"2024-11-08 20:29","pubTimestamp":1731068964,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Geron .Geron Corporation has secured $250 million in funding through a loan agreement with Pharmakon Advisors and a synthetic royalty deal with Royalty Pharma, strengthening its financial position. This includes a $125 million loan tranche and $125 million from Royalty Pharma for tiered royalties on U.S. sales of RYTELO. Geron’s strong Q3 performance, with $28.2 million in RYTELO sales, underscores its commercial potential, supported by the company’s strategic investments and leadership changes to drive future growth in the biopharmaceutical sector.For a thorough assessment of GERN stock, go to TipRanks’ Stock Analysis page.Icahn to Boost Stake in CVR Energy to 81% by Cutting IEP’s Dividend. Amazon Considers Additional Multi-Billion Dollar Investment in Anthropic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zzQJwVxfC_2TzhvJl13Lkg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/geron-secures-250m-funding-strong-122924685.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-secures-250m-funding-strong-122924685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GERN"],"gpt_icon":0},{"id":"2481159558","title":"Geron Corp reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481159558","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481159558?lang=en_us&edition=fundamental","pubTime":"2024-11-08 04:46","pubTimestamp":1731012404,"startTime":"0","endTime":"0","summary":"Geron Corp reports results for the quarter ended in September 30 - Earnings Summary  Geron Corp GERN.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended September 30, high","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME3SI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN"],"gpt_icon":0},{"id":"2481132706","title":"Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2481132706","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481132706?lang=en_us&edition=fundamental","pubTime":"2024-11-08 00:42","pubTimestamp":1730997734,"startTime":"0","endTime":"0","summary":"Geron  said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma  and investment funds managed by Pharmakon Advisors.The company said $250 million in cash was provided at closing, with another $125 million in debt available.Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.Price: 4.29, Change: +0.02, Percent Change: +0.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RPRX","BK4007","GERN","BK4139"],"gpt_icon":0},{"id":"2481386011","title":"Geron Corporation : H.c. Wainwright Raises Target Price to $9 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2481386011","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481386011?lang=en_us&edition=fundamental","pubTime":"2024-11-08 00:16","pubTimestamp":1730996175,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nAZN2L16YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2481376661","title":"Geron's Q3 Loss Narrows, Revenue Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2481376661","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481376661?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:37","pubTimestamp":1730990256,"startTime":"0","endTime":"0","summary":"Geron  reported a Q3 loss Thursday of $0.04 per diluted share, narrowing from a loss of $0.08 a year earlier.Analysts surveyed by Capital IQ expected a loss of $0.09.Revenue for the quarter ended Sept. 30 was $28.3 million, up from $164,000 a year earlier.Analysts polled by Capital IQ expected $19 million.For fiscal 2024, the company said it expects total operating expenses of about $260 million to $270 million.The company also said its existing cash, cash equivalents and marketable securities, together with anticipated revenue from US sales of Rytelo, will be sufficient to fund its projected operating requirements for at least the next 12 months.Price: 4.43, Change: +0.16, Percent Change: +3.63","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GERN"],"gpt_icon":0},{"id":"2481189914","title":"Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481189914","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481189914?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:20","pubTimestamp":1730985606,"startTime":"0","endTime":"0","summary":"Geron  came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.56%. A quarter ago, it was expected that this drugmaker would post a loss of $0.11 per share when it actually produced a loss of $0.10, delivering a surprise of 9.09%.Geron , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $28.27 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 34.96%. This compares to year-ago revenues of $0.16 million. The company has topped consensus revenue estimates three times over the last four quarters.Geron shares have added about 102.4% since the beginning of the year versus the S&P 500's gain of 24.3%.While Geron has outperformed the market so far this year, the question that comes to investors' minds is: ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/132juehTNIyEUn7pK7.GPA--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-gern-reports-q3-loss-132006852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GERN"],"gpt_icon":0},{"id":"2481348901","title":"Geron reports Q3 EPS (4c), consensus (8c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481348901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481348901?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:57","pubTimestamp":1730984275,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $28.27M, consensus $19.01M. “This has been a transformative year for Geron (GERN), following our first FDA approval and commerci...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/geron-reports-q3-eps-4c-consensus-8c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/geron-reports-q3-eps-4c-consensus-8c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GERN"],"gpt_icon":0},{"id":"2481901393","title":"Geron sees FY24 operating expenses $260M-$270M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481901393","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481901393?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:55","pubTimestamp":1730984117,"startTime":"0","endTime":"0","summary":"The company said, “For fiscal year 2024, we expect total operating expenses to be in the range of approximately $260 million to $270 million, which...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/geron-sees-fy24-operating-expenses-260m-270m?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/geron-sees-fy24-operating-expenses-260m-270m?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GERN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.geron.com","stockEarnings":[{"period":"1week","weight":0.0847},{"period":"1month","weight":0.0099},{"period":"3month","weight":-0.1202},{"period":"6month","weight":0.2349},{"period":"1year","weight":1.0812},{"period":"ytd","weight":0.9431}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.592593,"avgChangeRate":0.12214},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.042814},{"month":3,"riseRate":0.481481,"avgChangeRate":0.072721},{"month":4,"riseRate":0.518519,"avgChangeRate":0.018201},{"month":5,"riseRate":0.444444,"avgChangeRate":0.005244},{"month":6,"riseRate":0.5,"avgChangeRate":0.079392},{"month":7,"riseRate":0.464286,"avgChangeRate":-0.008248},{"month":8,"riseRate":0.517241,"avgChangeRate":0.044567},{"month":9,"riseRate":0.310345,"avgChangeRate":-0.010897},{"month":10,"riseRate":0.551724,"avgChangeRate":0.018154},{"month":11,"riseRate":0.448276,"avgChangeRate":0.039443},{"month":12,"riseRate":0.321429,"avgChangeRate":-0.012791}],"exchange":"NASDAQ","name":"Geron","nameEN":"Geron"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Geron(GERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Geron,GERN,Geron股票,Geron股票老虎,Geron股票老虎国际,Geron行情,Geron股票行情,Geron股价,Geron股市,Geron股票价格,Geron股票交易,Geron股票购买,Geron股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Geron(GERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}